AA
ASND icon

Ancora Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Ancora Advisors’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.2K Hold
12
– – ﹤0.01% 1703
2026
Q1 		$2.75K Hold
12
– – ﹤0.01% 2083
2025
Q4 		$2.56K Buy
+12
New +$2.48K ﹤0.01% 2090

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Ancora Advisors's ASND Position: Q2 2026 in Review

Ancora Advisors held its Ascendis Pharma A/S (ASND) position steady in Q2 2026 at 12 shares worth $3.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1703.

Ancora Advisors first reported a position in ASND in Q4 2025 and has held it in 3 quarters since. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Ancora Advisors held 12 shares of Ascendis Pharma A/S worth $3.2K as of Q2 2026.
  • Ancora Advisors left its Ascendis Pharma A/S share count unchanged in Q2 2026.
  • Ascendis Pharma A/S made up ﹤0.01% of Ancora Advisors's portfolio in Q2 2026, its #1703 holding.
  • Ancora Advisors first reported a position in Ascendis Pharma A/S in Q4 2025 and has held it in 3 quarters since.
  • 313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Ancora Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.